NANT Pancreatic Cancer Vaccine: Combination Immunotherapy With High-affinity Natural Killer (haNK) in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy.

Trial Profile

NANT Pancreatic Cancer Vaccine: Combination Immunotherapy With High-affinity Natural Killer (haNK) in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs ALT 803 (Primary) ; Avelumab (Primary) ; Bevacizumab (Primary) ; Capecitabine (Primary) ; Cyclophosphamide (Primary) ; ETBX 011 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; GI 4000 (Primary) ; High-affinity Natural Killer-NantKwest (Primary) ; Omega-3-acid ethyl esters (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms QUILT-3.060
  • Sponsors NantKwest
  • Most Recent Events

    • 13 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 06 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top